Review




Structured Review

Santa Cruz Biotechnology id3
Figure 1. Id1 Is a Target of the TbRI Inhibitor in PCTCs and in a Patient-Derived Mouse Model for Glioma (A) The genes were regulated by the treatment with 2 mM TbRI inhibitor for 3 hr in 11 human glioma PCTCs with a fold change over 1.4 or below 0.6 and a p < 0.001. (B) <t>ID3,</t> ID1, Smad7, and RhoB transcript levels were determined by qRT-PCR analysis. GAPDH RNA levels were used as an internal normalization control. *p < 0.05; **p < 0.001. Data are presented as means ± SD. (C and D) Cells from GBM1 and GBM2 neuro- spheres were inoculated in the brain of immuno- compromised mice. Twenty days after surgery, mice were orally treated twice a day with 100 mg/kg of TbRI inhibitor for 30 days. (C) Tumor area was quantified. (D) Images from the entire mouse brains were obtained by MRI (arrowheads indicate tumors). (E) Immunohistochemistry for Id1 (upper panel) and double immunofluorescence for Id1 and CD31 (middle panel) were performed in tumors generated by GBM neurospheres. For immunoflu- orescence, nuclei were counterstained with Hoechst. Scale bar, 100 mm. Representative images are shown and percentage of Id1-positive cells was calculated (lower panel). Data are pre- sented as means ± SD. (F) Cells from GBM1 neurospheres were inocu- lated in the brain of immunocompromised mice. Forty days after surgery, mice were orally treated twice a day with 100 mg/kg of TbRI inhibitor for 10 days. Subsequently, 10 mm slides from mouse brains were stained with H&E and tumors were localized and microdissected. ID1 tran- script levels were determined by qRT-PCR (n = 4 for vehicle; n = 3 for TbRI inhibitor). Data are presented as means ± SD. See also Fig- ure S1.
Id3, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 152 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/immunohistochemistry+microarray+based+expression+data/Id3+Antibody/pm21156287-254-14-21
Average 93 stars, based on 152 article reviews
id3 - by Bioz Stars, 2026-11
93/100 stars

Images

1) Product Images from "TGF-β Receptor Inhibitors Target the CD44(high)/Id1(high) Glioma-Initiating Cell Population in Human Glioblastoma."

Article Title: TGF-β Receptor Inhibitors Target the CD44(high)/Id1(high) Glioma-Initiating Cell Population in Human Glioblastoma.

Journal: Cancer cell

doi: 10.1016/j.ccr.2010.10.023

Figure 1. Id1 Is a Target of the TbRI Inhibitor in PCTCs and in a Patient-Derived Mouse Model for Glioma (A) The genes were regulated by the treatment with 2 mM TbRI inhibitor for 3 hr in 11 human glioma PCTCs with a fold change over 1.4 or below 0.6 and a p < 0.001. (B) ID3, ID1, Smad7, and RhoB transcript levels were determined by qRT-PCR analysis. GAPDH RNA levels were used as an internal normalization control. *p < 0.05; **p < 0.001. Data are presented as means ± SD. (C and D) Cells from GBM1 and GBM2 neuro- spheres were inoculated in the brain of immuno- compromised mice. Twenty days after surgery, mice were orally treated twice a day with 100 mg/kg of TbRI inhibitor for 30 days. (C) Tumor area was quantified. (D) Images from the entire mouse brains were obtained by MRI (arrowheads indicate tumors). (E) Immunohistochemistry for Id1 (upper panel) and double immunofluorescence for Id1 and CD31 (middle panel) were performed in tumors generated by GBM neurospheres. For immunoflu- orescence, nuclei were counterstained with Hoechst. Scale bar, 100 mm. Representative images are shown and percentage of Id1-positive cells was calculated (lower panel). Data are pre- sented as means ± SD. (F) Cells from GBM1 neurospheres were inocu- lated in the brain of immunocompromised mice. Forty days after surgery, mice were orally treated twice a day with 100 mg/kg of TbRI inhibitor for 10 days. Subsequently, 10 mm slides from mouse brains were stained with H&E and tumors were localized and microdissected. ID1 tran- script levels were determined by qRT-PCR (n = 4 for vehicle; n = 3 for TbRI inhibitor). Data are presented as means ± SD. See also Fig- ure S1.
Figure Legend Snippet: Figure 1. Id1 Is a Target of the TbRI Inhibitor in PCTCs and in a Patient-Derived Mouse Model for Glioma (A) The genes were regulated by the treatment with 2 mM TbRI inhibitor for 3 hr in 11 human glioma PCTCs with a fold change over 1.4 or below 0.6 and a p < 0.001. (B) ID3, ID1, Smad7, and RhoB transcript levels were determined by qRT-PCR analysis. GAPDH RNA levels were used as an internal normalization control. *p < 0.05; **p < 0.001. Data are presented as means ± SD. (C and D) Cells from GBM1 and GBM2 neuro- spheres were inoculated in the brain of immuno- compromised mice. Twenty days after surgery, mice were orally treated twice a day with 100 mg/kg of TbRI inhibitor for 30 days. (C) Tumor area was quantified. (D) Images from the entire mouse brains were obtained by MRI (arrowheads indicate tumors). (E) Immunohistochemistry for Id1 (upper panel) and double immunofluorescence for Id1 and CD31 (middle panel) were performed in tumors generated by GBM neurospheres. For immunoflu- orescence, nuclei were counterstained with Hoechst. Scale bar, 100 mm. Representative images are shown and percentage of Id1-positive cells was calculated (lower panel). Data are pre- sented as means ± SD. (F) Cells from GBM1 neurospheres were inocu- lated in the brain of immunocompromised mice. Forty days after surgery, mice were orally treated twice a day with 100 mg/kg of TbRI inhibitor for 10 days. Subsequently, 10 mm slides from mouse brains were stained with H&E and tumors were localized and microdissected. ID1 tran- script levels were determined by qRT-PCR (n = 4 for vehicle; n = 3 for TbRI inhibitor). Data are presented as means ± SD. See also Fig- ure S1.

Techniques Used: Derivative Assay, Quantitative RT-PCR, Control, Immunohistochemistry, Generated, Staining

Figure 4. Patient-Derived Neurospheres Have a CD44high/Id1high Cell Population (A) Cells from GBM1 neurospheres were dissociated and seeded on coverslips. Immunocytochemistry for Id1and CD44 was performed and nuclei were counter- stained with Hoechst. Scale bar, 10 mm. Quantification of Id1 and CD44 expression levels per cell is shown. (B) FACS analysis of CD44 levels was performed in GBM neurospheres (upper panel). Isotype control is shown. Cells with high or low levels of CD44 from the indicated GBM neurospheres were sorted by FACS and CD44, ID1, ID2, and ID3 transcript levels were determined by qRT-PCR (lower panels). *p < 0.01; **p < 0.001 compared to CD44low. Data are presented as means ± SD. (C) Cells from GBM1 neurospheres were sorted by FACS according to CD44 levels, and the levels of Id1, Id3, and tubulin were determined by immunoblotting. See also Figure S4.
Figure Legend Snippet: Figure 4. Patient-Derived Neurospheres Have a CD44high/Id1high Cell Population (A) Cells from GBM1 neurospheres were dissociated and seeded on coverslips. Immunocytochemistry for Id1and CD44 was performed and nuclei were counter- stained with Hoechst. Scale bar, 10 mm. Quantification of Id1 and CD44 expression levels per cell is shown. (B) FACS analysis of CD44 levels was performed in GBM neurospheres (upper panel). Isotype control is shown. Cells with high or low levels of CD44 from the indicated GBM neurospheres were sorted by FACS and CD44, ID1, ID2, and ID3 transcript levels were determined by qRT-PCR (lower panels). *p < 0.01; **p < 0.001 compared to CD44low. Data are presented as means ± SD. (C) Cells from GBM1 neurospheres were sorted by FACS according to CD44 levels, and the levels of Id1, Id3, and tubulin were determined by immunoblotting. See also Figure S4.

Techniques Used: Derivative Assay, Immunocytochemistry, Staining, Expressing, Control, Quantitative RT-PCR, Western Blot

Figure 6. Id Proteins Mediate the Effect of TGF-b on the CD44high Population and the Oncogenic Potential of GBM Neurospheres (A) Cells from GBM1 were infected with the indicated lentivirus. Neurospheres were treated with 100 pM TGF-b1 for 3 hr, 2 mM TbRI inhibitor for 8 hr, or left untreated, and the levels of Id1, Id3, p-Smad2, Smad2, and tubulin were determined by immunoblotting. (B) Cells from GBM1 neurospheres previously infected with the indicated lentivirus were treated with 100 pM TGF-b or 2 mM TbRI inhibitor for 7 days or left untreated. FACS analysis of CD44 levels (left panel) and quantification of the frequency of CD44high cells are shown (right panel). Bars represent the percent of CD44high cells in untreated, TGF-b-treated, and TbRI inhibitor-treated lentiviral-infected neurospheres, as indicated. Data are presented as means. (C–E) Cells from GBM1 neurospheres previously infected with the indicated lentivirus were treated for 7 days with 2 mM TbRI inhibitor, or left untreated. Subse- quently, cells were dissociated, counted, and equal numbers of cells were inoculated in the brain of NOD-SCID mice. (C) Images from the entire mouse brains were obtained by MRI. Arrowheads indicate tumors. (D) Tumor area was quantified (p = 0.004 comparing mice inoculated with untreated neurospheres with mice inoculated with neurospheres treated with the TbRI inhibitor; p = 0.002 comparing mice inoculated with neurospheres infected with the lentivirus control with mice inoculated with neurospheres infected with the sh2 ID1/ID3). (E) Tumor incidence was determined. Data are presented as means ± SD. (F–H) Cells from GBM1 neurospheres previously infected with the indicated lentivirus were treated during 7 days with 2 mM TbRI inhibitor or left untreated. Subse- quently, cells were dissociated, counted, and equal numbers of cells were inoculated in the brain of immunocompromised mice. (F) Images from the entire mouse brains were obtained by MRI. Arrowheads indicate tumors. (G) Tumor area was quantified (p = 0.04 comparing mice inoculated with control neurospheres with mice inoculated with Id1 overexpressing neurospheres), and (H) tumor incidence was determined. Data are presented as means ± SD. See also Figure S6.
Figure Legend Snippet: Figure 6. Id Proteins Mediate the Effect of TGF-b on the CD44high Population and the Oncogenic Potential of GBM Neurospheres (A) Cells from GBM1 were infected with the indicated lentivirus. Neurospheres were treated with 100 pM TGF-b1 for 3 hr, 2 mM TbRI inhibitor for 8 hr, or left untreated, and the levels of Id1, Id3, p-Smad2, Smad2, and tubulin were determined by immunoblotting. (B) Cells from GBM1 neurospheres previously infected with the indicated lentivirus were treated with 100 pM TGF-b or 2 mM TbRI inhibitor for 7 days or left untreated. FACS analysis of CD44 levels (left panel) and quantification of the frequency of CD44high cells are shown (right panel). Bars represent the percent of CD44high cells in untreated, TGF-b-treated, and TbRI inhibitor-treated lentiviral-infected neurospheres, as indicated. Data are presented as means. (C–E) Cells from GBM1 neurospheres previously infected with the indicated lentivirus were treated for 7 days with 2 mM TbRI inhibitor, or left untreated. Subse- quently, cells were dissociated, counted, and equal numbers of cells were inoculated in the brain of NOD-SCID mice. (C) Images from the entire mouse brains were obtained by MRI. Arrowheads indicate tumors. (D) Tumor area was quantified (p = 0.004 comparing mice inoculated with untreated neurospheres with mice inoculated with neurospheres treated with the TbRI inhibitor; p = 0.002 comparing mice inoculated with neurospheres infected with the lentivirus control with mice inoculated with neurospheres infected with the sh2 ID1/ID3). (E) Tumor incidence was determined. Data are presented as means ± SD. (F–H) Cells from GBM1 neurospheres previously infected with the indicated lentivirus were treated during 7 days with 2 mM TbRI inhibitor or left untreated. Subse- quently, cells were dissociated, counted, and equal numbers of cells were inoculated in the brain of immunocompromised mice. (F) Images from the entire mouse brains were obtained by MRI. Arrowheads indicate tumors. (G) Tumor area was quantified (p = 0.04 comparing mice inoculated with control neurospheres with mice inoculated with Id1 overexpressing neurospheres), and (H) tumor incidence was determined. Data are presented as means ± SD. See also Figure S6.

Techniques Used: Infection, Western Blot, Control

Figure 7. TbRI Inhibitor Decreases Id1, Id3, and CD44 Levels in Tumors and Prevents Tumor Recurrence in Vivo (A) Scheme showing the experimental procedure. (B and C) Cells from GBM1 neurospheres were inoculated in the brain of immunocompromised mice. Forty days after surgery, mice were orally treated twice a day with 100 mg/kg of TbRI inhibitor for 10 days. Subsequently, human tumor cells were isolated from the brain of mice treated or untreated with TbRI inhibitor through sorting of human MHC-I-positive cells. (B) ID1, ID3, and CD44 transcripts levels were determined by qRT-PCR, and (C) CD44 levels were assessed by FACS. Isotype control is shown. Data are presented as means ± SD. (D and E) Human tumor cells obtained from mice treated or untreated with the TbRI inhibitor were inoculated in the brain of secondary mice. (D) Thirty days after surgery, images from the entire mouse brains were obtained by MRI, tumor area was quantified (n = 4 mice inoculated with cells from untreated mice; n = 8 mice inoculated with cells from TbRI inhibitor treated mice), and (E) tumor incidence was determined. Data are presented as means ± SD.
Figure Legend Snippet: Figure 7. TbRI Inhibitor Decreases Id1, Id3, and CD44 Levels in Tumors and Prevents Tumor Recurrence in Vivo (A) Scheme showing the experimental procedure. (B and C) Cells from GBM1 neurospheres were inoculated in the brain of immunocompromised mice. Forty days after surgery, mice were orally treated twice a day with 100 mg/kg of TbRI inhibitor for 10 days. Subsequently, human tumor cells were isolated from the brain of mice treated or untreated with TbRI inhibitor through sorting of human MHC-I-positive cells. (B) ID1, ID3, and CD44 transcripts levels were determined by qRT-PCR, and (C) CD44 levels were assessed by FACS. Isotype control is shown. Data are presented as means ± SD. (D and E) Human tumor cells obtained from mice treated or untreated with the TbRI inhibitor were inoculated in the brain of secondary mice. (D) Thirty days after surgery, images from the entire mouse brains were obtained by MRI, tumor area was quantified (n = 4 mice inoculated with cells from untreated mice; n = 8 mice inoculated with cells from TbRI inhibitor treated mice), and (E) tumor incidence was determined. Data are presented as means ± SD.

Techniques Used: In Vivo, Isolation, Quantitative RT-PCR, Control

Figure 8. Id1 and CD44 Coexpression Correlates with Overall Survival in GBM Patients (A) A tissue microarray of 43 different GBM patients was stained with an antibody against Id1 and the frequency of Id1-positive nuclei was calculated. (B) CD44/Id1 and CD31/Id3 double immunofluorescence of samples from GBM patients. Magnification of the indicated areas stained with Id1/CD44 and Id3/ CD31 are shown in the right panels. Nuclei were counterstained with Hoechst. Scale bar, 50 mm. (C) CD44, Id1, and CD31 immunohistochemistry of samples from GBM patients. Scale bar, 100 mm. (D) Kaplan-Meier curves showing that the overall survival of patients with both ID1 mRNA levels upregulated R3-fold and CD44 mRNA levels upregulated R10-fold is significantly lower than the rest of the patients (p = 0.03) by log-rank test. Data obtained from the Repository for Molecular Brain Neoplasia Data (REMBRANDT) program form the National Cancer Institute. See also Figure S7.
Figure Legend Snippet: Figure 8. Id1 and CD44 Coexpression Correlates with Overall Survival in GBM Patients (A) A tissue microarray of 43 different GBM patients was stained with an antibody against Id1 and the frequency of Id1-positive nuclei was calculated. (B) CD44/Id1 and CD31/Id3 double immunofluorescence of samples from GBM patients. Magnification of the indicated areas stained with Id1/CD44 and Id3/ CD31 are shown in the right panels. Nuclei were counterstained with Hoechst. Scale bar, 50 mm. (C) CD44, Id1, and CD31 immunohistochemistry of samples from GBM patients. Scale bar, 100 mm. (D) Kaplan-Meier curves showing that the overall survival of patients with both ID1 mRNA levels upregulated R3-fold and CD44 mRNA levels upregulated R10-fold is significantly lower than the rest of the patients (p = 0.03) by log-rank test. Data obtained from the Repository for Molecular Brain Neoplasia Data (REMBRANDT) program form the National Cancer Institute. See also Figure S7.

Techniques Used: Microarray, Staining, Immunohistochemistry

Related Articles

Chromatin Immunoprecipitation:

Article Title: Autophagy-mediated ID1 turnover dictates chemo-resistant fate in ovarian cancer stem cells
Article Snippet: .. ABCG2 Rabbit A17908 ABclonal, MA, USA ID1 Mouse sc-133104 SCBT, TX, USA ID2 Mouse sc-398104 SCBT, TX, USA ID3 Mouse sc-56712 SCBT, TX, USA ID4 Mouse sc-365656 SCBT, TX, USA LAMP1 Mouse H4A3 DSHB, IA, USA LC3B Rabbit 2775S CST, MA, USA NANOG Mouse sc-293121 SCBT, TX, USA OCT-3/4 Rat MAB1759 Biotechne, MN, USA p62/SQSTM1 Rabbit ab155686 CST, MA, USA SLC31A1 Rabbit A0773 ABclonal, MA, USA SLC31A1 (I.H.C. grade) Rabbit APREST72883 Sigma Aldrich, DA, DE TCF12 Rabbit A4146 ABclonal, MA, USA TCF12 (ChIP grade) Mouse sc-28364-X SCBT, TX, USA TCF12 Rabbit 11825 CST, MA, USA α-Tubulin Mouse T5168 Sigma Aldrich, DA, DE Rabbit Gamma Globulin Control Rabbit 31887 Invitrogen, USA Mouse Gamma Globulin Control Mouse 31878 Invitrogen, USA .. Alexa FluorTM 568 Rat A11004 Thermofisher, MA USA Anti-Mouse IgG HRP conjugate Goat 4416 Thermofisher, MA USA Anti-Rabbit IgG HRP conjugate Goat A6154 Thermofisher, MA USA DyLightTM 488 Rabbit 35552 Thermofisher, MA USA DyLightTM 633 Mouse 35512 Thermofisher, MA USA Table S2.

Control:

Article Title: Autophagy-mediated ID1 turnover dictates chemo-resistant fate in ovarian cancer stem cells
Article Snippet: .. ABCG2 Rabbit A17908 ABclonal, MA, USA ID1 Mouse sc-133104 SCBT, TX, USA ID2 Mouse sc-398104 SCBT, TX, USA ID3 Mouse sc-56712 SCBT, TX, USA ID4 Mouse sc-365656 SCBT, TX, USA LAMP1 Mouse H4A3 DSHB, IA, USA LC3B Rabbit 2775S CST, MA, USA NANOG Mouse sc-293121 SCBT, TX, USA OCT-3/4 Rat MAB1759 Biotechne, MN, USA p62/SQSTM1 Rabbit ab155686 CST, MA, USA SLC31A1 Rabbit A0773 ABclonal, MA, USA SLC31A1 (I.H.C. grade) Rabbit APREST72883 Sigma Aldrich, DA, DE TCF12 Rabbit A4146 ABclonal, MA, USA TCF12 (ChIP grade) Mouse sc-28364-X SCBT, TX, USA TCF12 Rabbit 11825 CST, MA, USA α-Tubulin Mouse T5168 Sigma Aldrich, DA, DE Rabbit Gamma Globulin Control Rabbit 31887 Invitrogen, USA Mouse Gamma Globulin Control Mouse 31878 Invitrogen, USA .. Alexa FluorTM 568 Rat A11004 Thermofisher, MA USA Anti-Mouse IgG HRP conjugate Goat 4416 Thermofisher, MA USA Anti-Rabbit IgG HRP conjugate Goat A6154 Thermofisher, MA USA DyLightTM 488 Rabbit 35552 Thermofisher, MA USA DyLightTM 633 Mouse 35512 Thermofisher, MA USA Table S2.

Incubation:

Article Title: AMH protects the ovary from doxorubicin by regulating cell fate and the response to DNA damage
Article Snippet: .. Following fixation in 4%PFA for 10min, granulosa cells were permeabilized 1%TritonX, washed with 0.1% PBST and blocked in 2.5%BSA/PBST before being incubated overnight with γ-H2AX (1:200, cell signaling #2577) and Id3 antibody (1:100, Santa Cruz, sc-56712). .. The granulosa cells were then rinsed with PBST and incubated for 1h with secondary antibody Alexa Fluor 594 donkey anti-rabbit IgG (1:200, # A-21207, Invitrogen) and Alexa Fluor 488 donkey anti-mouse IgG (1:200, ab150105, Abcam) before being counterstained with Hoechst.

Article Title: Bone morphogenetic protein 10 is increased in pre-capillary pulmonary hypertension patients
Article Snippet: .. The sections were permeabilized, blocked and incubated at 4°C overnight with primary antibodies against BMP10 (diluted 1:200; Biorbyt), cardiac troponin T (cTnT, diluted 1:500; Abcam), and ID3 (diluted 1:50, Santa Cruz). .. Samples were then incubated for 1h at room temperature with anti-rabbit secondary antibody conjugated with Alexa-488 and anti-mouse secondary antibody conjugated with Alexa-647 (diluted 1:500; Abcam).

Article Title: AMH protects the ovary from doxorubicin by regulating cell fate and the response to DNA damage.
Article Snippet: Colonies were fixed and stained with a solution of 80% crystal violet and 20% methanol, then 30% v/v acetic acid was added and absorbance was recorded at 595 to 600 nm in the VICTOR Multilabel Plate Reader (PerkinElmer). .. Following fixation and permeabilization, GCs were incubated with primary antibodies against γ- H2AX (cell signaling) and Id3 antibody (Santa Cruz) and secondary antibodies Alexa Fluor 594 donkey anti- rabbit IgG (Invitrogen) and Alexa Fluor 488 donkey anti- mouse IgG (Abcam) before being counterstained with Hoechst. ..

Immunofluorescence:

Article Title: AMH protects the ovary from doxorubicin by regulating cell fate and the response to DNA damage.
Article Snippet: Briefly, RNAish was developed using the RNAscope Mutiplex Fluorescent Reagent Kit v2 assay or the RNAscope 2.5 HD Reagent Kit (RED) (ACD Bio). .. For Immunofluorescence the primary antibodies used were LRH- 1 (R&D system), pH2AX (cell signaling), Id3 (Santa Cruz), and for secondary antibodies, Alexa Fluor 594 donkey anti- rabbit IgG (Invitrogen) and Alexa Fluor 488 donkey anti- mouse IgG (1Abcam). .. TUNEL- assay was performed using the Click- iT Plus (Invitrogen).



Similar Products

86
Human Protein Atlas immunohistochemistry microarray based expression data
Immunohistochemistry Microarray Based Expression Data, supplied by Human Protein Atlas, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/immunohistochemistry+microarray+based+expression+data/data+immunohistochemistry/bio_rxiv__64898__2025__12__09__693329-120-11-17
Average 86 stars, based on 1 article reviews
immunohistochemistry microarray based expression data - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier

Image Search Results